Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine

This placebo-controlled Phase III study of tocilizumab in patients hospitalised with severe Covid-19 pneumonia found no improvement in clinical status (primary endpoint; between-group difference -1.0; 95% CI -2.5 to 0; p=0.31) or mortality (19.7% v 19.4%; p=0.94) at day 28.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news